{
    "symbol": "CTLT",
    "quarter": 4,
    "year": 2022,
    "date": "2022-08-29 13:16:03",
    "content": " Our projection of fiscal 2023 revenue growth is driven by our non-COVID business, which is expected to grow organically by more than 25% at constant currency due to several factors, including growth expansions of existing asset that came online in the past year, such as our new drug substance lines in medicine and drug product lines in Bloomington and Europe, maximizing efficiencies in other areas of our global network, including those that manufacture our gummy format in previously announced build out our cell therapy and plasmid offerings in Europe and U.S. adding new capacity in the next two quarters, including the opening of eight previously announced gene therapy switch and BWI an additional tech substance capacity in Bloomington. Thank you for your question. Thank you for your question. Thank you for your question. Thank you for your question. Thank you for your question. Thank you for your question. Thank you for your question. Thank you for your question. Thank you for your question. Thank you for your question."
}